Delcath Systems Inc DCTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DCTH is a good fit for your portfolio.
News
-
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Delcath Systems Closes $7 Million Private Placement
-
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
-
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
-
Delcath Systems Announces $7 Million Private Placement
-
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $5.26
- Day Range
- $5.28–5.50
- 52-Week Range
- $2.25–7.99
- Bid/Ask
- $5.30 / $5.38
- Market Cap
- $134.83 Mil
- Volume/Avg
- 165,118 / 209,003
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 76
- Website
- https://www.delcath.com
Comparables
Valuation
|
Metric
|
DCTH
|
NYKD
|
PCVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.65 | 2.43 | 4.64 |
Price/Sales | 41.66 | 28.54 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DCTH
NYKD
PCVX
Financial Strength
|
Metric
|
DCTH
|
NYKD
|
PCVX
|
|---|---|---|---|
Quick Ratio | 2.00 | 7.91 | 7.43 |
Current Ratio | 2.26 | 8.04 | 7.54 |
Interest Coverage | −32.13 | −235.75 | — |
Quick Ratio
DCTH
NYKD
PCVX
Profitability
|
Metric
|
DCTH
|
NYKD
|
PCVX
|
|---|---|---|---|
Return on Assets (Normalized) | −101.25% | −19.18% | −21.69% |
Return on Equity (Normalized) | −739.46% | −26.31% | −23.31% |
Return on Invested Capital (Normalized) | −195.68% | −30.96% | −28.13% |
Return on Assets
DCTH
NYKD
PCVX
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Rtpzjlrx | Ctryf | $185.4 Bil | |
SYK
| Stryker Corp | Xrqxfxhxd | Tqpz | $127.7 Bil | |
BSX
| Boston Scientific Corp | Xgzpwrdd | Mcjhgf | $107.6 Bil | |
MDT
| Medtronic PLC | Lyzfvjyz | Pcjbwk | $105.9 Bil | |
DXCM
| DexCom Inc | Hcscdddvr | Hys | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Zmrvcyzlv | Yyyxgm | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Nrfdsdtyq | Bwm | $24.6 Bil | |
ALGN
| Align Technology Inc | Mfdfqcyty | Vqtrlm | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Fwnwcfyp | Rllqbhw | $18.7 Bil | |
PODD
| Insulet Corp | Fnmdmkmcjh | Qvvpn | $11.6 Bil |